Status:
RECRUITING
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
Lead Sponsor:
Changi General Hospital
Collaborating Sponsors:
National University of Singapore
Conditions:
Obesity and Type 2 Diabetes
NAFLD - Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adul...
Detailed Description
Design This a randomized controlled study comparing a standard weight management program of face-to-face (F2F) consults with doctors (endocrinologists and sports medicine physicians) and dieticians as...
Eligibility Criteria
Inclusion
- Adults aged 21-70
- Body mass index \> 27.5 kg/m2
- Waist circumference \> 90 cm in men or 80 cm in women
- Suboptimal control of type 2 diabetes (HbA1c \> 6.5%) AND/OR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)
Exclusion
- Men who drink \> 21 units/week and women who drink \> 14 units/week of alcohol
- Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation)
- Illness with life expectancy of less than 6 months
- Inability to comply with written instructions in English
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06890169
Start Date
May 1 2025
End Date
August 31 2027
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changi General Hospital
Singapore, Singapore, 529889